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Abstract
We have characterized the ATPase activity of a sensitive and five progressively daunorubicin resistant Ehrlich ascites
tumor cell lines passaged in mice. For the nine different modulators of drug resistance that we have studied, the ATPase
activity first rose with the modulator concentration and then declined. We analyzed the ATPase activity profiles in terms of
an activation constant and an inhibition constant for each of the nine drugs and six cell lines. In this series of cell lines, the
drug-stimulatable ATPase activity was directly proportional to the amount of P-glycoprotein. Pumping of daunorubicin was
also correlated with the amount of P-glycoprotein, except that, for a highly passaged line more daunorubicin was pumped
than could be accounted for by the content of P-glycoprotein. Between the 12th and the 36th passage an additional source
of resistance emerged, which was not correlated with P-glycoprotein. Pumping of daunorubicin was negatively correlated
with the cell volume for the different lines. q 1997 Elsevier Science B.V.
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1. Introduction
Most cancer deaths arise because the tumors have
metastasized and have become resistant to chemo-
therapy. Until we find ways to prevent cancer en-
tirely, or to prevent the formation of metastases,
overcoming drug resistance will remain the main
hope to save lives. P-Glycoprotein, the product of the
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DK-2200 Copenhagen N, Denmark. Fax: q45 3532 7420. E-mail:
T.Litman@mfi.ku.dk
MDR1 gene, is an important contributor to multidrug
w xresistance in many cell types 1,2 and has been found
w xto be expressed in a substantial number of tumors 3 .
P-Glycoprotein acts by pumping out its drug sub-
strate from within the tumor cell, reducing the effec-
tiveness of the chemotherapeutic agent that is being
administered.
P-Glycoprotein is a member of the ABC ATP
.binding cassette superfamily of transporters, among
which are several ATP-dependent, substrate specific
w xtransport proteins 4–6 . By analogy to other traffic
ATPases, P-glycoprotein is considered to be a mem-
brane-bound transporter, which couples hydrolysis of
ATP to the export of drugs to the outside of the cell
0925-4439r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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w x7,8 . Substantial evidence has accumulated in sup-
port of ATP-dependent drug extrusion by P-glyco-
w xprotein 9–11 , whereas little is known about the
coupling mechanism between transport and ATP
splitting by this transporter. That indeed there is
coupling between the cytoplasmatic catalytic sites for
ATP hydrolysis and the sites for drug binding and
transport in the membrane, is suggested by the stimu-
lation of the ATPase activity by many P-glycoprotein
w xsubstrates 12–14 .
An analysis of the amino acid sequence of P-
w xglycoprotein 15,16 suggests that it consists of two
duplicated halves, each with a cytoplasmatically sided
ATP binding site, both of which have been shown to
w xbe catalytically active 17 . The preferred substrate
w xfor hydrolysis by P-glycoprotein is MgATP 18 ,
while vanadate, a pentacoordinate phosphorus transi-
tion state analogue, is an effective inhibitor of the
w xP-glycoprotein ATPase 14 , although at higher con-
 .centrations micromolar than are required for inhibi-
 .tion of P-type ATPases nanomolar .
In the present study of P-glycoprotein associated
ATPase activity, it is assumed that drug-induced ATP
hydrolysis is reflecting the interaction between the
substrate and the ATPase activation site of P-glyco-
w xprotein 19 . Thus, different drugs can be character-
ized with respect to their affinity to P-glycoprotein.
Seeing that P-glycoprotein mediated ATP hydrolysis
and substrate translocation are linked events, we might
get valuable information on the transport function of
P-glycoprotein, especially if the ATPase activity
studies are combined with an analysis of drug trans-
port.
Major efforts have been put into finding
clinically-useful reversers of P-glycoprotein, agents
that can block its action, leading to the renewed
accumulation of drugs within erstwhile resistant cells.
w xVery many such reversers have been identified 20,21
and have been characterized kinetically in terms of
w xtheir affinity for P-glycoprotein 11,22 . The first
generation of reversers of P-glycoprotein, drugs such
w x w x w xas verapamil 23 , cyclosporin A 24 , quinidine 25 ,
w x.and amiodarone 26 have not proved very useful in
the clinic, while second-generation modulators are
w xbeing developed 27 . Secure knowledge of the mech-
anism of action of P-glycoprotein must be the basis
for further advances in designing new and more
effective reversers.
We have here characterized a number of differen-
tially resistant Ehrlich tumor cell lines, with the aim
of relating their ATPase activity profiles i.e. the dose
.response curves for a variety of drugs to the degree
of resistance and P-glycoprotein expression. Such a
comparative study of effects of reversers in different
cell lines at various stages of development of resis-
tance is the first of its kind, and it may provide
significant information on how the properties of mul-
tidrug resistant cells — and of P-glycoprotein —
change with the development of drug resistance.
2. Materials and methods
2.1. Tumor cells
Six different Ehrlich cell lines were used for the
ATPase activity characterization: EHR2, the parental
drug sensitive cell line.
EHR2r0.8, a daunorubicin resistant subline,
treated with daunorubicin 0.8 mgrkg=4 weekly
 .50% of the LD dose . Cells from passages 6, 12,10
36 and 72, in the following termed P6, P12, P36 and
P72 were used.
EHR2r1.3, resistant, treated with daunorubicin 1.3
mgrkg for more than 300 passages. The cells were
maintained in vivo in NMRIrDBA mice by intraperi-
toneal inoculation. Drug was not administered in the
last passage before the experiments.
2.2. Isolation of microsomal membranes
The cells were washed with Ringer’s medium
NaCl, 148.7 mM; K HPO , 2.55 mM; KH PO ,2 4 2 4
.0.45 mM; MgSO , 1.2 mM; pH 7.4 before being4
resuspended in 10 ml lysis buffer Hepes-Tris, 10
mM; EDTA, 5 mM; EGTA, 5 mM; dithiothreitol, 2
. mM; pH 7.4 containing protease inhibitors phenyl-
methylsulfonyl fluoride, 2 mM; aprotinin, 5 mgrml;
.pepstatin, 10 mgrml; leupeptin, 10 mgrml . This
and all subsequent steps were performed at 48C. Cells
were lysed by nitrogen cavitation Parr Instrument
.Co., Moline, IL, USA at 1200 psi for 20 min. Nuclei
were sedimented by centrifugation at 300=g for 10
min, and subsequently mitochondria were removed
by centrifugation at 4000=g for 10 min. In a third
 .and final centrifugation 45 000=g, 60 min the
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microsomal fraction was sedimented. The pellet was
resuspended in 1 ml of lysis buffer and homogenized
by aspiration ten times through a 27 gauge syringe.
 .Aliquots of 150 ml containing 1–2 mg proteinrml
were rapidly frozen in liquid nitrogen and stored at
y808C until analysis.
2.3. ATPase acti˝ity assay
The P-glycoprotein associated ATPase activity was
w xdetermined according to Borgnia et al. 28 , by quan-
titating the release of inorganic phosphate from ATP,
using a sensitive, colorimetric assay originally de-
w xscribed by Chifflet et al. 29 and later modified by
w xDoige et al. 30 . The microsomes were thawed on
ice before diluting to a protein concentration of 20
mgrml in ice-cold ATPase assay medium ATP, 3
mM; KCl, 50 mM; MgSO , 2.5 mM; dithiothreitol, 34
.mM; Tris-HCl, 25 mM; pH 7.0 containing 0.5 mM
 . EGTA to inhibit Ca-ATPases , 2 mM ouabain to
. inhibit the NarK-ATPase , and 3 mM azide to
.inhibit mitochondrial ATPase . Each series of experi-
ments was carried out in a 96-well microtiter plate,
with reaction volumes of 50 mlrwell corresponding
to 1 mg proteinrwell. Incubation with the various
drugs was started by transferring the plate from ice to
378C for 1 h, and terminated by addition of 200 ml
ice-cold stopping medium ammonium molybdate,
 .  .0.2% wrv ; sulfuric acid, 1.3% vrv ; SDS, 0.9%
 .  .wrv ; trichloroacetic acid, 2.3% wrv ; freshly pre-
 ..pared ascorbic acid, 1% wrv to each well. After
30 min incubation at room temperature, the released
phosphate was quantitated colorimetrically in a mi-
 .cro-plate reader Bio-Tek Instruments, VT USA at
620 nm. Background and control experiments with
ATPase assay buffer alone, samples incubated on ice,
and samples incubated with 500 mM vanadate in-
.hibiting the P-glycoprotein ATPase were obtained in
parallel and subtracted from the measurements. Wa-
ter-insoluble drugs were dissolved in ethanol or
 .DMSO; the solvent constituted max. 1% vrv of the
total volume, and was shown not to affect the AT-
Pase activity.
2.4. Drug accumulation assay
The uptake of daunorubicin was followed with
 .time 5, 15, 29, 45, 60 min at 378C as described by
w xSkovsgaard 31 , and the effect of various chemosen-
sitizers and other drugs on the accumulation of
daunorubicin was investigated. To the incubation
medium NaCl, 57 mM; KCl, 5 mM; MgSO , 1.34
mM; NaH PO , 9 mM; Na HPO , 51 mM; fetal calf2 4 2 4
 . .serum, 5% vrv ; pH 7.45 was added glucose to 10
mM and the test drug at various concentrations be-
low and above the K for interaction with the P-m
.glycoprotein ATPase . Control experiments without
glucose but with 10 mM sodium azide were per-
formed to obtain the maximum accumulation level of
Daunorubicin. The uptake of daunorubicin was quan-
titated fluorometrically Hitachi F3010 spectro-
fluorometer, Tokyo, Japan; excitation 470 nm, emis-
.sion 585 nm , but in those cases where quenching of
the fluorescence signal by the modulator was ob-
w3 xserved, H Daunorubicin was used and measured in
 .a scintillation counter Packard, IL, USA .
2.5. Volume measurements
The cell volumes of various Ehrlich cell lines were
w xmeasured using a Coulter Counter 32 . The volume
distribution profiles were analyzed, and the median
cell volume calculated. Cells were resuspended in
filtered Ringer medium Millipore, pore size 0.45
.mm to 40 000 cellsrml. Cell volumes were mea-
sured in a Coulter counter model ZB equipped with a
Coulter Channellyzer C1000, which enabled the me-
dian cell volume of the population to be recorded and
stored. Tube orifice diameter was 100 mm. Calibra-
tion was carried out with 13.5 mm diameter
polystyrene latex beads.
2.6. Chemicals
D-Verapamil and "-verapamil were kindly pro-
 .vided by Knoll AG Ludwigshafen, Germany . All
other chemicals were of analytical grade, purchased
 .either from Merck Darmstadt, Germany or from
 .Sigma St. Louis, MO, USA .
3. Results
3.1. ATPase acti˝ity profiles of six progressi˝ely
resistant cell lines
The vanadate-sensitive ATPase activity in mem-
brane preparations from six progressively resistant
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 .Fig. 1. ATPase profiles of microsomes obtained from wild type, and five progressively resistant Ehrlich ascites tumor cells. A The
 .figure depicts the absolute vanadate-sensitive ATPase activity as a function of D-verapamil Dex-verapamil in the concentration range:
 .0.1–400 mM on a log scale. B Relative ATPase activity in the low concentration range: 0–25 mM of D-verapamil. The lines drawn10
 2.  2 . .are fitted to a modified form of the Michaelis-Menten equation: V s K K V qK V SqV S r K K qK SqS . . . 1S . 1 2 0 2 1 2 1 2 2
Ehrlich cell lines is depicted in Fig. 1. This figure
compiles the results of a typical set of experiments in
which the ATPase activity is plotted as a function of
the drug concentration of, in this case, the modulator
D-verapamil. The bottom data set is for the sensitive
 .  .wild type Ehrlich cell line EHR2 , the lines P6,
P12, P36, and P72 were selected for 6, 12, 36, and 72
passages with daunorubicin at 50% LD , while the10
line EHR2r1.3 was selected with daunorubicin at
LD for more than 300 passages. For the modulators10
that we will report on in this paper, the ATPase
activity first rises and then falls with increasing drug
concentration. We have fitted the data in Fig. 1 solid
.lines to the equation:
K K V qK V SqV S21 2 0 2 1 2V s . . . 1 .S. 2K K qK SqS1 2 2
where V is the ATPase activity as a function of the(S)
substrate concentration S, V is the basal activity the0
Fig. 2. Correlation between basal ATPase activity, P-glycoprotein content evaluated by Western blot analysis as described in Litman et
w x.  .  .al. 34 , daunorubicin DNR accumulation and relative resistance in wild type v , and five progressively resistant Ehrlich ascites tumor
 .  .  .  .  .  .cell lines: P6 ^ , P12 ’ , P36 \ , P72 % , and EHR2r1.3 B . The mean and SEM ns6–10 of the ATPase activity is depicted
in the figures. The dotted lines are first order regression fits to the data, but the slopes of the regression lines do not differ significantly
 .from zero F-test, P)0.1 .
( )T. Litman et al.rBiochimica et Biophysica Acta 1361 1997 147–158 151
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 .Fig. 4. The effect of twenty drugs on steady-state DNR accumulation by resistant Ehrlich EHR2r1.3 cells. Intracellular accumulation
was measured after 60 min incubation at 378C and 5 mM DNR at a series of dilutions of the test drugs. Each dose response course is
 .  6 .determined in triplicate, and the mean and SEM of the DNR accumulation pmolr10 cells is depicted. The lines drawn are obtained
 . n  nby curve-fitting to a modified form of the Michaelis-Menten equation which includes the Hill coefficient, VsV q V yV S r S q0 max 0
.K , using the Marquardt-Levenberg algorithm.i
.activity in the absence of modulator , V is the1
 .maximal enzyme activity if only activation occurred ,
and K is the substrate concentration that gives half1
this maximal increment in ATPase activity. V is the2
activity at infinite concentration of the modulator,
and K is the substrate concentration which gives2
half-maximal reduction of ATPase activity from the
value V . This equation is based on conventional1
w xenzyme kinetics algebra 33 for a model that has an
activity V with one S bound, and a, lower, activity1
of magnitude V with two molecules of S bound.2
Table 1 presents the kinetic characterization of the
drug modulatable ATPase activity for these six cell
lines for nine different modulators. Both the basal
 .  .V and the maximal ATPase activity V rise with0 1
increasing degree of resistance in the P lines, and are
well above the respective value for the sensitive
strain.
3.2. Correlation with parameters of drug resistance
We have investigated how the parameters of Eq.
 .1 correlate both with the amount of P-glycoprotein,
the relative resistance, and the reciprocal of the extent
of the steady-state daunorubicin accumulation that
w xhad been determined for each cell line 34 . The
 .  .  .Fig. 3. Correlation between maximum ATPase activity and A P-glycoprotein content, B 1rDaunorubicin accumulation, and C
 .  .  .  .  .relative resistance in a wild type v , and five progressively resistant EAT cell lines: P6 ^ , P12 ’ , P36 \ , P72 % , and
 .  .  .EHR2r1.3 B . In A the line is a first order regression fit to the data, in B the lines drawn are first order regressions fitted to the data
 .with the exception of the EHR2r1.3 points, and in C a non-linear fit is applied to all points except to the EHR2r1.3 point.
"-verapamil is the racemic mixture of the two enantiomers.
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reciprocal of the daunorubicin accumulation is a mea-
sure of pumping activity of P-glycoprotein The
equilibrium level of drug accumulation can be ex-
 .pressed as dr kqd , where d is the rate of simple
w xdiffusion, and k is the pump rate 35 . The reciprocal
 .of this function is kqd rd, which is proportional to
.k, and hence to P-glycoprotein .
Fig. 2 shows the basal ATPase activity, V , as a0
function of these three parameters. V is higher for0
all of the cell lines which have been exposed to
daunorubicin. There is no significant increase in V0
with increasing amount of P-glycoprotein, resistance,
 .or 1r daunorubicin . In contrast, Fig. 3 shows that
the maximal, drug-stimulated ATPase activity is
highly correlated with the P-glycoprotein content
 .  . Fig. 3A , well correlated with 1r daunorubicin Fig.
.3B , and increases to an ill-defined plateau with
 .relative resistance Fig. 3C .
3.3. Correlation with chemosensitizing potential
We also investigated the possibility of a relation-
ship between the ATPase modulating properties and
the chemosensitizing potential of the drugs tested.
The accumulation of 5 mM daunorubicin in mul-
tidrug resistant EHR2r1.3 cells was followed with
time, and the intracellular concentration after a 60-min
incubation was considered as the steady-state level.
The effect of twenty representative drugs on the
steady-state accumulation of daunorubicin is illus-
trated in Fig. 4. The curves have been plotted as a
function of the concentration of drug, added together
with DNR. The lines drawn are fitted to a modified
form of the Michaelis-Menten equation which in-
cludes the Hill coefficient, as several of the drugs
displayed sigmoidicity with respect to DNR accumu-
lation. Thus, the equation leaving the Hill number, n,
to be determined by the curve-fitting program, was:
Sn
VsV q V yV . . . . n0 max 0 V0nS q K =intr /Vmax
2 .
where V is the amount of DNR accumulated at a
concentration S of the drug, V is the basal, intra-0
cellular DNR level in the absence of modulator, Vmax
Table 2
Kinetic parameters for reversal of DNR accumulation in resistant
EHR2r1.3 cells
 .Drug K mM nintr
"-Verapamil 0.93 1.6
Dipyridamole 1.83 2.1
Diltiazem 18.7 1.2
Fluphenazine 0.95 1.8
Trifluoperazine 1.34 1.9
Triflupromazine 11.1 2.3
Chlorpromazine 11.7 2.5
Promethazine 10.5 2.0
Amiodarone 0.4 1.8
Pimozide 0.72 0.7
Propafenone 4.79 1.0
Quinidine 0.61 1.5
Progesterone 3.97 1.5
Spironolactone 12.5 1.6
Terfenadine 1.23 2.0
Mefloquine 1.71 1.3
Cyclosporin A 0.19 1.9
Vinblastine 0.56 1.8
aColchicine ND ND
aMethotrexate ND ND
K is the intrinsic Michaelis parameter, the drug concentrationintr
at which the activity of P-glycoprotein is blocked by half. n is
the Hill coefficient.
a The DNR accumulation did not reach a plateau with colchicine
or with methotrexate.
Fig. 5. Correlation between the reciprocal of daunorubicin accu-
 .  .mulation 1rDNR and cell volume of the wild type v , and
 .  .five progressively resistant EAT cell lines: P6 ^ , P12 ’ , P36
 .  .  .\ , P72 % , and EHR2r1.3 B . The line is a first order
 .regression to the data r s0.961 .
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is the DNR accumulation at maximum concentration
of modulator, and K is the drug concentrationintr
which blocks the activity of P-glycoprotein by half
 w x.for a derivation of K , see Lan et al. 36 . Theintr
kinetic parameters, K , and the Hill coefficient, n,intr
obtained for the 20 different drugs are listed in Table
2.
3.4. Correlation between drug accumulation and cell
˝olume
We have also measured the resting volume of the
six cell lines of Ehrlich ascites tumor cells. Fig. 5 is a
plot of the cells ability to pump out daunorubicin
 .1rDNR against the cell volume. The straight line is
a first order regression to the data and has a correla-
tion coefficient of 0.961. It would seem that the cell’s
ability to pump out daunorubicin is highly correlated
with a decrease in cell volume.
4. Discussion
The data of Fig. 1, showing drug-stimulatable
ATPase activity of P-glycoprotein, are similar to
those reported previously from the laboratories of
w x w x w xSarkadi 12 , Ambudkar 13 , Sharom 37 , Senior
w x w x38 and Ling 39 . We are not, however, aware of
any quantitative analysis of such ATPase activity
profiles. The rising portion of these curves presents
 .no conceptual difficulties. Presumably some site s
on P-glycoprotein binds the modulator bringing about
activation of the ATPase. Membranes derived from
sensitive cells possessed marginal, if any, drug-
stimulatable ATPase activity. On the other hand, the
four sequentially derived MDR cell lines had incre-
mental maximal ATPase activities in the order P6-
P72. The established MDR line, EHR2r1.3, had a
maximal drug-stimulated ATPase activity which was
between that of P12 and P36.
It appears that most of the substrates give about
the same degree of maximal ATPase stimulation,
about two-fold compared to the basal level. This
suggests that a true V is measured, a V which ismax max
independent of the substrate. The affinity for the
ATPase, reflected by the K parameter, did vary1
considerably amongst substrates, but it was practi-
cally constant for a given drug along the different cell
lines. This implies, that substrates can be well charac-
terized by the relative affinity for interaction with
P-glycoprotein, and that the substrate affinity of the
drug-stimulated ATPase only varied little if at all in
the course of resistance development.
What can we say about the inhibitory phase, how-
ever? Does it represent binding to a true, specific site
on P-glycoprotein or is it merely an unspecific,
w xmembrane perturbating effect 40 ? Some insight into
this question can be obtained by considering a wide
range of modulators as is recorded in Table 1. How-
ever, the interpretation of the parameters describing
the inhibition part of the ATPase activity, K and V ,2 2
is difficult. Both K and V seem to vary consider-2 2
ably, and some of the values get very high. However,
several of the estimates of these parameters were
very dependent on the high substrate concentrations
in this ‘‘noisy’’ region of the ATPase activity pro-
files, and it could well be that inhibition of ATPase
activity was not total, or it might even be artifactual,
w xdue to unspecific, membrane perturbating effects 40 .
The values obtained for the less resistant cell lines
 .EHR2, P6, P12 are somewhat uncertain due to the
low stimulation observed on a relatively high back-
ground activity. On the other hand, the low K2
values observed with, e.g. amiodarone and dipyri-
damole indicate that the inhibitory interaction with
the P-glycoprotein associated ATPase is for these
drugs specific and not merely a membrane effect.
The nature of the basal ATPase activity has been
w x w xdiscussed by Senior et al. 41 and Borgnia et al. 28
who both suggest that an endogenous, still unknown
substrate present in the membranes is providing the
stimulus for the P-glycoprotein ATPase. Another
viewpoint is that the basal activity represents the
uncoupled activity of the ATPase, as suggested by
w xSharom et al. 42 . What we find is that the basal
activity is indeed higher in resistant cells but this
 .does not increase with increasing resistance Fig. 2 .
In our hands, the vanadate-sensitive, basal ATPase
activity does increase with low P-glycoprotein con-
centrations. However, a correlation between basal
ATPase activity and higher levels of P-glycoprotein
is not seen, and may represent a response of the cells
to early exposure to daunorubicin.
When one now considers the dependence of the
 .maximal ATPase activity V for nine different drugs,1
a very clear correlation between V and the content of1
( )T. Litman et al.rBiochimica et Biophysica Acta 1361 1997 147–158156
 .  .  .Fig. 6. Correlation between A 1rDNR accumulation, B relative resistance, and P-glycoprotein content in wild type v , and five
 .  .  .  .  .progressively resistant EAT cell lines: P6 ^ , P12 ’ , P36 \ , P72 % , and EHR2r1.3 B . The line drawn is a first order
regression fit to the points.
P-glycoprotein is apparent for all six cell lines Fig.
.3A . Perhaps not surprisingly the ATPase activity
depends directly on the presence of P-glycoprotein.
A correlation is less clear, however, when one looks
at V as a function of 1rdaunorubicin. Here, the1
correlation is good for all cell lines excepting the
 .highly passaged EHR2r1.3 line Fig. 3B . The
straight lines in Fig. 3B are linear regressions with
the data point for this cell line omitted. It would
appear that for the EHR2r1.3 cell line another path-
way for daunorubicin efflux is present which is not
connected to ATPase activity. Thus, if this cell line
had only an ATPase-associated pump for daunoru-
bicin, the degree of daunorubicin accumulation would
be twice that which is indeed found the point sym-
bolized by the solid square would be shifted to the
.left . Looking now at the plots of V vs. relative1
 .resistance Fig. 3C , it seems as if the increase in
maximal ATPase activity does not keep pace with the
increase in resistance, which directly points to the
emergence of new sources of resistance as the degree
of selection is increased; this is in accordance with
w xprevious reports 43–48 . One cell line, again, seems
to set apart from the others, namely EHR2r1.3,
which may be due to the different ‘‘history’’ of this
line. The EHR2r1.3 has been subcultered for more
than 300 passages by now, and with this probably has
acquired a phenotype with multiple mechanisms of
.resistance , which one would expect to be different
from that of any short-term selected cell line.
This is emphasized when one plots the data that
w xLitman et al. 34 have accumulated on these same
 .lines. Fig. 6 is a plot of 1r daunorubicin against
 .P-glycoprotein Fig. 6A and of the relative resis-
 .tance against the content of P-glycoprotein Fig. 6B .
The pumping of daunorubicin is well correlated with
the P-glycoprotein content except for the aberrant
.EHR2r1.3 line . That 1rDNR accumulation is di-
rectly proportional to the P-glycoprotein content sug-
gests that a simple relationship exists between the
number of P-glycoprotein molecules and the number
of drug molecules pumped. This speaks against coop-
erativity between P-glycoprotein molecules, acting as
di- or oligomers, theories advanced by Naito and
w x w xTsuruo 49 and Poruchynsky and Ling 50 .
Considering Fig. 6B, after 12 passages the resis-
tance towards daunorubicin rises far more steeply
than would be expected from the P-glycoprotein
content; this is consistent with the emergence of new
sources of resistance.
Consider now, the data on the effect of reversers
 .on daunorubicin accumulation Fig. 4 . All drugs,
excepting methotrexate which is not a substrate of
w xP-glycoprotein 51 , induced a dose-dependent in-
crease in the DNR accumulation. The drug accumula-
tion curves, most of which appeared sigmoidal, could
be fitted to a modified Michaelis-Menten equation,
which includes the Hill coefficient and the intrinsic
 .Michaelis constant for pump inhibition Table 2 . For
nine of these reversers we have values for Michaelis
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constants derived by activation of the ATPase Table
.1 and for the effect on daunorubicin accumulation
 .Table 2 . For seven of the reversers the two inhibi-
tion constants are very similar, for diltiazem, the
constant for ATPase activation is twice as high as
would be expected for diltiazem’s effect on drug
accumulation. For promethazine, the constant for AT-
Pase activation is ten times as high as would be
predicted by the corresponding value of K . Weintr
have no explanation for this discrepancy. Indeed, one
might have expected less of an accord between the
two sets of Michaelis parameters since Fig. 3B and
Fig. 6 show that for the EHR2r1.3 strain, part of the
reduction in daunorubicin accumulation was indepen-
dent of the action of P-glycoprotein.
Interestingly, the majority of the drugs had Hill
coefficients for reversal of DNR accumulation which
were closer to two than to one. This finding strongly
suggest cooperati˝ity between pairs of reverser
molecules, i.e. more than one drug-binding site on
P-glycoprotein, which is in agreement with the AT-
Pase activity studies in the accompanying papers,
 .Litman et al. current issue of BBA , implying maybe
numerous sites of interaction. The present work also
accords with reports on non-competitive interactions
between reversers and transport substrates of P-
w xglycoprotein 52–54 . The data are also consistent
with previous reports on cooperativity between pairs
w xof reversers 35 and between pairs of substrate
w xmolecules 54 . It is not clear if there is any structural
basis for the lack of cooperativity observed with four
of the 20 drugs. Vinblastine, which is an established
transport substrate of P-glycoprotein and thus is ex-
pected to compete with DNR for transport, had a Hill
coefficient of 2. Thus, both transport substrates and
reversers which are not known to be transport sub-
strates behave similarly in their effects on reversing
daunorubicin accumulation. Consequently, such data
do not allow one to exclude the possibility that
reversers are P-glycoprotein transport substrates. A
direct approach would be to test whether the accumu-
lation of the reverser itself is affected by inhibition of
P-glycoprotein, but the very fast transmembrane dif-
w xfusion of many reversers 55 complicates this analy-
sis.
An interesting finding is the high correlation be-
tween the ability to pump out daunorubicin and the
decrease in cell volume observed with these increas-
 .ingly resistant cell lines Fig. 5 . It should be noted
that the volume measurements are performed in the
absence of any added substrate of P-glycoprotein.
w xZeuthen and Stein 56 suggested that P-glycoprotein
behave as an ‘‘osmotic engine’’, pumping out water
as it pumps out substrate. Were this model to hold,
the decreased volume in the more resistant cell lines
might indicate that they are pumping out water in the
absence of added substrate, perhaps stimulated by an
endogenous substrate. The high negative correlation
that we see between 1rdaunorubicin accumulation
and cellular volume would thus represent two aspects
of the cells ability to pump: The former being a
measure of pumping in the presence of added sub-
strate, the latter in the presence of the proposed, but
hitherto unidentified, endogenous substrate.
Acknowledgements
The authors are indebted to drs. Yehuda Assaraf,
Gera Eytan, and Mario Borgnia from Technion Haifa,
.Israel for kindly introducing the ATPase assay
methodology. We wish to thank Dr Else K. Hoff-
mann at the Institute of Biological Chemistry, Yhe
 .August Krogh Institute Copenhagen for providing
the Coulter Counter facilities. Thomas Litman is the
recipient of research grants from the Danish Cancer
 .Society grant no. 11 94 039 , the Novo Nordisk
Foundation, and ‘‘Tribute to the Danes through
Scholarships in Israel’’. The authors thank Birthe
Lynderup, Marianne Knudsen and Marianne Fregil
for excellent technical assistance.
References
w x  .1 R.J. Arceci, J. Am. Soc. Hematol. 81 1993 2215–2222.
w x2 T. Skovsgaard, D. Nielsen, C. Maare, K. Wassermann,
International review of cytology, Vol. 156, in: K.W. Jeon, J.
 .Jarvik Eds. , Academic Press, San Diego, 1994, pp. 77–157.
w x3 D. Nielsen, T. Skovsgaard, Biochim. Biophys. Acta. 1139
 .1992 169–183.
w x  .4 C.F. Higgins, Annu. Rev. Cell. Biol. 8 1992 67–113.
w x  .5 J.H. Kaplan, Cell 72 1993 13–18.
w x  .6 M. Dean, R. Allikmets, Current Opin. Genet. Dev. 5 1995
779–785.
w x  .7 M.M. Gottesman, I. Pastan, Annu. Rev. Biochem. 62 1993
385–427.
w x8 C.R. Leveille-Webster, I.M. Arias, J. Membr. Biol. 143
 .1995 89–102.
( )T. Litman et al.rBiochimica et Biophysica Acta 1361 1997 147–158158
w x9 M. Horio, M.M. Gottesman, I. Pastan, Proc. Natl. Acad. Sci.
 .USA 85 1988 3580–3584.
w x10 C.A. Doige, F.J. Sharom, Biochim. Biophys. Acta. 1109
 .1992 161–171.
w x  .11 A.B. Shapiro, V. Ling, J. Bioenerg. Biomembr. 27 1995
7–13.
w x12 B. Sarkadi, E.M. Price, R.C. Boucher, U.A. Germann, G.A.
 .Scarborough, J. Biol. Chem. 267 1992 4854–4858.
w x13 S.V. Ambudkar, I.H. Lelong, J. Zhang, C.O. Cardarelli,
M.M. Gottesman, I. Pastan, Proc. Natl. Acad. Sci. USA 89
 .1992 8472–8476.
w x14 A.E. Senior, M.K. Al-Shawi, I.L. Urbatsch, J Bioenerg.
 .Biomembr. 27 1995 31–36.
w x15 C. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, M.M.
 .Gottesman, I.B. Roninson, Cell 47 1986 381–389.
w x  .16 P. Gros, J. Croop, D.E. Housman, Cell 47 1986 371–380.
w x17 I.L. Urbatsch, B. Sankaran, S. Bhagat, A.E. Senior, J. Biol.
 .Chem. 270 1995 26956–26961.
w x  .18 M.K. Al-Shawi, A.E. Senior, J. Biol. Chem. 268 1993
4197–4206.
w x  .19 U.S. Rao, J. Biol. Chem. 270 1995 6686–6690.
w x  .20 J.M. Ford, W.N. Hait, Pharmacol. Rev. 42 1990 155–199.
w x21 M. Alvarez, K. Paull, A. Monks, C. Hose, J.-S. Lee, J.
 .Weinstein, M. Grever, S.E. Bates, J. Clin. Invest. 95 1995
2205–2214.
w x22 D. Piwnica-Worms, V.V. Rao, J.F. Kronauge, J.M. Croop,
 .Biochemistry 34 1995 12210–12220.
w x23 T. Tsuruo, H. Iida, S. Tsukagoshi, Y. Sakurai, Cancer Res.
 .41 1981 1967–1972.
w x  .24 P.R. Twentyman, Biochem. Pharmacol. 43 1992 109–117.
w x25 T. Tsuruo, H. Iida, Y. Kitatani, K. Yokota, S. Tsukagoshi,
 .Y. Yakurai, Cancer. Res. 44 1984 4303–4307.
w x26 B. Chauffert, M. Martin, A. Hammann, M.F. Michel, F.
 .Martin, Cancer Res. 46 1986 825–830.
w x27 J.-S. Lee, K. Paull, M. Alvarez, C. Hose, A. Monks, M.
 .Grever, A.T. Fojo, S.E. Bates, Mol. Pharmacol. 46 1994
627–638.
w x28 M. Borgnia, G.D. Eytan, Y.G. Assaraf, J. Biol. Chem. 271
 .1996 3163–3171.
w x29 S. Chifflet, T.R. Chiesa, S. Tolosa, Anal. Biochem. 168
 .1988 1–4.
w x30 C.A. Doige, X. Yu, F.J. Sharom, Biochim. Biophys. Acta.
 .1109 1992 149–160.
w x  .31 T. Skovsgaard, Biochem. Pharmacol. 27 1978 1221–1227.
w x32 E.K. Hoffmann, L.O. Simonsen, I.H. Lambert, J Membr.
 .Biol. 78 1984 211–222.
w x33 W.D. Stein, Transport and diffusion across cell membranes,
Academic Press, San Diego, 1986.
w x34 T. Litman, D. Nielsen, T. Skovsgaard, K. Bukhave, Cell
 .Pharm. 2 1995 9–14.
w x35 S. Ayesh, Y.-M. Shao, W.D. Stein, Biochim. Biophys. Acta.
 .1316 1996 8–18.
w x36 L.B. Lan, S. Ayesh, E. Lyubimov, I. Pashinsky, W.D. Stein,
 .Cancer Chemother. Pharmacol. 38 1996 181–190.
w x37 F.J. Sharom, C.A. Doige, X.-H. Yu, Proc. Am. Assoc.
 .Cancer Res. 33, 1992, 2830 Abst. .
w x38 I.L. Urbatsch, M.K. Al-Shawi, A.E. Senior, Biochemistry
 .33 1994 7069–7076.
w x  .39 A.B. Shapiro, V. Ling, J. Biol. Chem. 269 1994 3745–
3754.
w x40 R.M. Wadkins, P.J. Houghton, Biochim. Biophys. Acta.
 .1153 1993 225–236.
w x41 A.E. Senior, M.K. Al-Shawi, I.L. Urbatsch, FEBS Lett. 377
 .1995 285–289.
w x42 F.J. Sharom, X. Yu, J.W.K. Chu, C.A. Doige, Biochem. J.
 .308 1995 381–390.
w x43 L.M. Garcia-Segura, J.A. Ferragut, A.V. Ferrer-Montiel,
P.V. Escriba, J.M. Gonzalez-Ros, Biochim. Biophys. Acta.´
 .1029 1990 191–195.
w x44 J.E. Gervasoni Jr., S.Z. Fields, S. Krishna, M.A. Baker, M.
Rosado, K. Thuraisamy, A.A. Hindenburg, R.N. Taub, Can-
 .cer Res. 51 1991 4955–4963.
w x45 S.P.C. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E.
Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V.
 .Duncan, R.G. Deeley, Science 258 1992 1650–1654.
w x46 J.M. LeCerf, S.B. Levy, Proc. Am. Assoc. Cancer Res. 33,
 .1992, 2732 Abst. .
w x  .47 Y.G. Assaraf, M. Borgnia, Anticancer Drugs 4 1993 395–
406.
w x48 G.L. Scheffer, P.L.J. Wijngaard, M.J. Flens, M.A. Izquierdo,
M.L. Slovak, H.M. Pinedo, C.J.L.M. Meijer, H.C. Clevers,
 .R.J. Scheper, Nature Medicine 1 1995 578–582.
w x49 M. Naito, T. Tsuruo, Biochem. Biophys. Res. Commun. 185
 .1992 284–290.
w x  .50 M.S. Poruchynsky, V. Ling, Biochemistry 33 1994 4163–
4174.
w x51 M.D. Norris, M. Haber, M. King, R.A. Davey, Biochem.
 .Biophys. Res. Commun. 165 1989 1435–1441.
w x  .52 I. Tamai, A.R. Safa, J. Biol. Chem. 266 1991 16796–
16800.
w x53 E. Pereira, M.N. Borrel, M. Fiallo, A. Garnier-Suillerot,
 .Biochim. Biophys. Acta. 1225 1994 209–216.
w x54 E.C. Spoelstra, H.V. Westerhoff, H.M. Pinedo, H. Dekker,
 .J. Lankelma, Eur. J. Biochem. 221 1994 363–373.
w x55 G.D. Eytan, R. Regev, G. Oren, Y.G. Assaraf, J. Biol.
 .Chem. 271 1996 12897–12902.
w x  .56 T. Zeuthen, W.D. Stein, J. Membr. Biol. 137 1994 179–
195.
